BAKER BROS. ADVISORS LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001263508

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 83 positions · Total reported value $19.13B · Top-10 concentration 74.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 24.2% · 8 new · 6 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +14.7% · vs SPY -0.1% · Prev Value $16.51B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, BAKER BROS. ADVISORS LP disclosed 83 equity positions with a combined reported value of $19.13B. The filing implies a focused portfolio: its ten largest positions account for 74.7% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were INCY ($3.49B), ONC ($2.51B), RVMD ($2.14B). By sector, the heaviest allocations are Health Care 99.4%, Other 0.6%.

Versus the prior quarter, BAKER BROS. ADVISORS LP opened 8 new positions, trimmed 6 and fully exited 8, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 82% of names.

The largest new positions opened in Q2 2026 were FTH ($32.16M), CYTK ($18.00M), NTLA ($15.74M).

Of the 8 positions fully exited versus the prior quarter, the largest were ABVX ($97.52M), SYRE ($50.44M), CNTA ($26.64M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • FTH FAETH THERAPEUTICS INC · $32.16M
  • CYTK CYTOKINETICS INC · $18.00M
  • NTLA INTELLIA THERAPEUTICS INC · $15.74M
  • PBLS PARABILIS MEDICINES INC · $13.69M
  • AVLN AVALYN PHARMA INC · $11.52M
  • TNGX TANGO THERAPEUTICS INC · $10.42M
  • AVTX AVALO THERAPEUTICS INC · $10.16M
  • IMNM IMMUNOME INC · $1.17M

Fully Exited (vs previous quarter)

  • ABVX ABIVAX SA · prev qtr: $97.52M
  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $50.44M
  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $26.64M
  • IMCR IMMUNOCORE HLDGS PLC · prev qtr: $22.14M
  • CTNM CONTINEUM THERAPEUTICS INC A · prev qtr: $18.56M
  • ARGX ARGENX SE · prev qtr: $18.38M
  • CMPS COMPASS PATHWAYS · prev qtr: $12.97M
  • PHVS PHARVARIS NV · prev qtr: $10.59M

Insider Transactions (Form 4)

Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 2,000 $396.61 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 13,740 $388.29 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 60,400 $383.01 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 81,729 $98.51 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 4,703 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 151,916 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 8,742 $98.51 SEC filing
2026-11-04 Buy MADRIGAL PHARMACEUTICALS, INC. 10,080 $368.11 SEC filing

All insider transactions →

Fund Profile

Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $19.13B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-73446 (status: Approved), registered 2012-03-05
  • Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 83 positions · $19.13B reported value (Q2 2026)
  • Top 10 holdings = 74.7% of reported value
  • Largest position: INCY (INCYTE CORP) at 18.2%
  • Average position size: $230.45M

Sector Tilt

  • Health Care 99.4%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 8 new, 10 added, 6 reduced, 8 exited
  • 59 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The BAKER BROS. ADVISORS LP fund appears to maintain a cautious stance, with a focus on Health Care sector, suggesting a belief in the stability and growth potential of this sector. 2. Key Moves: - Added: Revolution Medicines Inc. (RVMD) and Insmed Inc. (INSM), with significant increases in share count. - Reduced: None explicitly noted, but the slight increase in the share count of Incyte Corp. (INCY) indicates a minor addition. - Hold: The majority of holdings were held steady, with no significant changes in share count or position action. 3. Portfolio Structure: - Passive/Active: The fund seems to be active, as it added new positions and increased existing ones. - Sector Bias: Strong bias towards the Health Care sector, with 83% of the total value allocated to it. - Risk Appetite: The risk appetite is moderate, with a focus on established companies in the Health Care sector and no significant reduction in positions. 4. Per-Holding One-Liner: - INCY: Biotechnology company focused on developing therapies for immune-mediated diseases. - ONC: Biopharmaceutical company specializing in the development of treatments for various diseases. - RVMD: Biotechnology company focused on developing novel therapies for cancer and other diseases. - MDGL: Biotechnology company focused on the development of therapies for rare genetic diseases. - ACAD: Biotechnology company focused on developing treatments for neurological disorders. - KYMR: Biotechnology company focused on developing treatments for cancer and other diseases. - INSM: Biotechnology company focused on the development of therapies for rare genetic diseases. - KOD: Biotechnology company focused on the development of therapies for rare genetic diseases. - RYTM: Biotechnology company focused on the development of therapies for neurological disorders. - PRAX: Biotechnology company focused on the development of therapies for various diseases. 5. One-Sentence Style Summary: BAKER BROS. ADVISORS LP maintained a conservative approach, focusing on Health Care sector with a few strategic additions, reflecting a belief in the sector's stability and growth prospects.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.4%
Other 0.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 30.76M $3.49B 18.23%
Form 4 · 1 →
18.23%
Hold
2 8.80M $2.51B 13.11%
Form 4 · 1 →
13.11%
Hold
3 11.44M $2.14B 11.21%
11.21%
Add
4 2.14M $1.15B 6.02%
Form 4 · 5 →
6.02%
Hold
5 42.91M $1.09B 5.68%
5.68%
Hold
6 8.66M $992.73M 5.19%
5.19%
Hold
7 8.80M $937.84M 4.90%
4.90%
Add
8 19.92M $776.05M 4.06%
Form 4 · 86 →
4.06%
Hold
9 5.60M $622.27M 3.25%
3.25%
Hold
10 1.75M $586.95M 3.07%
3.07%
Hold
11 10.01M $524.59M 2.74%
2.74%
Hold
12 32.79M $477.70M 2.50%
2.50%
Reduce
13 4.03M $275.03M 1.44%
1.44%
Hold
14 33.01M $259.15M 1.35%
1.35%
Add
15 5.44M $209.42M 1.09%
1.09%
Hold
16 5.01M $186.72M 0.98%
0.98%
Add
17 2.83M $181.28M 0.95%
0.95%
Hold
18 4.72M $166.93M 0.87%
0.87%
Reduce
19 1.99M $162.43M 0.85%
0.85%
Hold
20 2.05M $162.36M 0.85%
0.85%
Hold
21 3.70M $150.40M 0.79%
0.79%
Reduce
22 11.05M $122.27M 0.64%
0.64%
Hold
23 4.66M $113.02M 0.59%
0.59%
Hold
24 3.34M $109.18M 0.57%
0.57%
Hold
25 4.35M $105.17M 0.55%
0.55%
Hold
26 9.51M $96.32M 0.50%
0.50%
Reduce
27 3.73M $96.05M 0.50%
0.50%
Hold
28 2.35M $87.99M 0.46%
0.46%
Hold
29 852.16K $83.07M 0.43%
0.43%
Hold
30 1.43M $76.88M 0.40%
0.40%
Hold
31 30.75M $69.16M 0.36%
0.36%
Hold
32 1.55M $64.47M 0.34%
0.34%
Hold
33 2.01M $56.63M 0.30%
0.30%
Hold
34 10.12M $53.96M 0.28%
0.28%
Hold
35 2.83M $52.89M 0.28%
0.28%
Add
36 445.98K $52.21M 0.27%
0.27%
Hold
37 10.89M $46.15M 0.24%
0.24%
Hold
38 905.19K $45.94M 0.24%
0.24%
Hold
39 1.18M $44.00M 0.23%
0.23%
Add
40 2.38M $43.78M 0.23%
0.23%
Add
41 2.68M $38.76M 0.20%
0.20%
Add
42 5.07M $37.34M 0.20%
0.20%
Hold
43 1.29M $32.16M 0.17%
0.17%
New
44 996.35K $32.11M 0.17%
0.17%
Hold
45 991.69K $31.19M 0.16%
0.16%
Hold
46 1.23M $27.34M 0.14%
0.14%
Reduce
47 4.00M $27.27M 0.14%
0.14%
Hold
48 844.82K $26.05M 0.14%
0.14%
Add
49 349.66K $25.57M 0.13%
0.13%
Hold
50 2.13M $24.74M 0.13%
0.13%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 91% · recall 91% · F1 91% · avg rank error 1.0 · Top-10 turnover 12%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% INCY · ONC · ACAD · MDGL · RYTM · MRTX · IMCR · RVMD · KYMR · ABCL INCY · ONC · ACAD · MDGL · RYTM · RVMD · KYMR · ABCL · BCYC · EWTX
2024-Q2 80% 80% 80% INCY · ONC · ACAD · MDGL · RVMD · RYTM · KYMR · BCYC · ABCL · EWTX INCY · ONC · ACAD · MDGL · RVMD · RYTM · INSM · BCYC · SMMT · KYMR
2024-Q3 100% 100% 100% INCY · ONC · ACAD · MDGL · RVMD · INSM · RYTM · BCYC · SMMT · KYMR ONC · INCY · ACAD · SMMT · MDGL · RVMD · RYTM · INSM · KYMR · BCYC
2024-Q4 90% 90% 90% ONC · INCY · ACAD · SMMT · MDGL · INSM · RVMD · RYTM · KYMR · BCYC INCY · ONC · ACAD · MDGL · SMMT · RVMD · INSM · RYTM · KYMR · KOD
2025-Q1 90% 90% 90% INCY · ONC · ACAD · MDGL · SMMT · INSM · RVMD · RYTM · KYMR · KOD ONC · INCY · ACAD · MDGL · SMMT · INSM · RYTM · RVMD · KYMR · ALKS
2025-Q2 100% 100% 100% ONC · INCY · ACAD · MDGL · SMMT · INSM · RYTM · RVMD · KYMR · ALKS ONC · INCY · ACAD · INSM · SMMT · MDGL · RYTM · RVMD · KYMR · ALKS
2025-Q3 90% 90% 90% INCY · ONC · ACAD · INSM · SMMT · MDGL · RVMD · RYTM · KYMR · ALKS ONC · INCY · MDGL · INSM · ACAD · SMMT · RYTM · RVMD · KYMR · KOD
2025-Q4 100% 100% 100% ONC · INCY · INSM · MDGL · ACAD · SMMT · RYTM · RVMD · KYMR · KOD INCY · ONC · MDGL · INSM · ACAD · RVMD · KYMR · SMMT · RYTM · KOD
2026-Q1 90% 90% 90% INCY · ONC · MDGL · ACAD · INSM · RVMD · KYMR · SMMT · RYTM · KOD INCY · ONC · INSM · MDGL · ACAD · RVMD · KOD · KYMR · SMMT · PRAX
2026-Q2 ★ 90% 90% 90% INCY · ONC · INSM · MDGL · ACAD · RVMD · KOD · KYMR · SMMT · PRAX INCY · ONC · RVMD · MDGL · ACAD · KYMR · INSM · KOD · RYTM · PRAX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did BAKER BROS. ADVISORS LP buy in 2026-Q2?

In its 2026-Q2 13F filing, BAKER BROS. ADVISORS LP reported 83 equity positions worth $19.13B in aggregate; its largest disclosed positions were INCY ($3.49B), ONC ($2.51B), RVMD ($2.14B).

How large is BAKER BROS. ADVISORS LP's portfolio?

BAKER BROS. ADVISORS LP reported $19.13B of long equity holdings across 83 positions as of 2026-Q2. Top-10 holdings account for 74.7% of reported value.

What is BAKER BROS. ADVISORS LP's investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/baker-bros-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →